Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA Medical Devices Law & Industry Report, in “FTC Action Risks Stifling Innovation, Health App Inventor Says,” by Michael Williamson.
Following is an excerpt:
Under the tacit agreement between the two agencies, Thompson explained the FTC will use its authority to ensure app makers aren’t making false claims about their products.
“In some ways, this makes political sense because it gets FDA out of the hot seat of going after small entrepreneurial app developers,” Thompson told Bloomberg BNA. He said rather than requiring premarket approval from the FDA, the FTC “uses its enforcement tools to go after what at least they consider to be shysters.”